Some existing and emerging therapies inhibiting membrane protein functions have significantly improved RA outcomes by reducing inflammation and modulating immune responses, like TNF inhibitors, IL-6 receptor antagonists, CTLA-4 agonists, and JAK inhibitors [43,44,45]. The gene discussed is CTLA4; the disease is rheumatoid arthritis.